Description
Xiamen Amoytop Biotech Co., Ltd. is a leading manufacturer of recombinant bio-pharmaceutical products in China, operating under cGMP (current Good Manufacturing Practice) standards. The company produces a range of biologics, including Molgramostim, Filgrastim, Oprelvekin, and Peginterferon alfa 2b, which are marketed domestically and exported to various countries. In addition to its pharmaceutical offerings, Xiamen Amoytop supplies bio-reagents for laboratory and research applications, such as Interleukin-4, TNF-alfa, IFN-gamma, IL-15, and SCF. Furthermore, the company is at the forefront of developing innovative drug delivery technologies, including their Y-shaped branch PEG Drug Delivery Technology for Pegfilgrastim, Pegsomatropin, and Peg-EPO. As the first and largest company to launch domestic Molgramostim in China, Xiamen Amoytop serves as a reference standard supplier to national institutes.
Services include:
– APIs (Active Pharmaceutical Ingredients)
– Biologics
– Contract Manufacturing (CMO/CDMO)
– Contract Research Organisation (CRO)
– Contract Services
– Consumer Goods
– Distributor
Xiamen Amoytop Biotech Co., Ltd. is dedicated to advancing biopharmaceutical research and production, ensuring high-quality products and services that meet the needs of the pharmaceutical industry. For more information, please visit amoytop.com.
Capabilities
Contact Information
Related Listings

CDMO Live Americas . October 20-21, Boston 2026
Experience the future of external manufacturing at CDMO Live, Rotterdam.
19-21st Oct 2026

AI + Digital Maturity in Contract Manufacturing 2026
Exclusive research roundtable on Day Zero of CDMO Live Americas 2026, in partnership with MasterControl










